R

RenovoRx
D

RNXT

1.69000
USD
-0.04
(-2.31%)
مغلق
حجم التداول
8,079
الربح لكل سهم
-0
العائد الربحي
-
P/E
-5
حجم السوق
76,268,869
المقالات
المزيد

العنوان: RenovoRx

القطاع: الرعاية الصحية
الصناعة: Biotechnology
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.